{"title":"英夫利昔单抗治疗日本强直性脊柱炎的疗效和安全性:11例回顾性研究","authors":"Yusuke Kubo, Masanobu Ohishi, Yasuharu Nakashima, Ken Okazaki, Jun-ichi Fukushi, Akiko Oyamada, Yukihide Iwamoto","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.</p><p><strong>Materials and methods: </strong>We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.</p><p><strong>Results: </strong>After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.</p><p><strong>Conclusions: </strong>Our results indicate that IFX is efficacious and safe for AS in Japanese patients.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"106 12","pages":"316-22"},"PeriodicalIF":0.0000,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases.\",\"authors\":\"Yusuke Kubo, Masanobu Ohishi, Yasuharu Nakashima, Ken Okazaki, Jun-ichi Fukushi, Akiko Oyamada, Yukihide Iwamoto\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.</p><p><strong>Materials and methods: </strong>We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.</p><p><strong>Results: </strong>After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.</p><p><strong>Conclusions: </strong>Our results indicate that IFX is efficacious and safe for AS in Japanese patients.</p>\",\"PeriodicalId\":12665,\"journal\":{\"name\":\"Fukuoka igaku zasshi = Hukuoka acta medica\",\"volume\":\"106 12\",\"pages\":\"316-22\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fukuoka igaku zasshi = Hukuoka acta medica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fukuoka igaku zasshi = Hukuoka acta medica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases.
Purpose: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.
Materials and methods: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.
Results: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.
Conclusions: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
